FDA Offers Criteria For Convening Advisory Committees In Draft Guidance
Executive Summary
FDA certainly has had its fair share of controversy in recent years, and now the agency is embracing controversy as a way to guide decisions about whether an issue is worthy of an advisory committee review
You may also be interested in...
Advisory Committee Vacancies Remain High As FDA Revs Up Search Efforts
With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies
FDA Aims To Up Transparency By Making Panel Materials Public Sooner
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications